再発性多形性膠芽腫治療薬市場：治療法別、タイプ別、地域別-規模、シェア、展望、機会分析-2022～2028年

脳腫瘍の発生率の増加は、予測期間中の再発性多形性膠芽腫治療薬市場の成長を促進すると予想されます。市場の主要企業は、新薬の開発、創出、商品化のための研究開発への投資を増やしており、近い将来、世界市場に有利な成長機会を生み出すと予想されます。しかし、効果的な治療法の欠如や、腫瘍の再発を効果的に防止する薬剤の不足が、予測期間中の市場成長を制限すると予想されます。

当レポートでは、世界の再発性多形性膠芽腫治療薬市場について調査分析し、市場の促進要因、抑制要因、市場機会、治療法・タイプ・地域別市場分析、企業プロファイルに関する情報を提供しています。

目次

第1章 調査目的・前提条件

第2章 市場概要

• レポートの説明
  • 市場の定義と範囲
• エグゼクティブサマリー
  • 市場内訳：治療法別
  • 市場内訳：タイプ別
  • 市場内訳：地域別
• コヒーレントオポチュニティマップ（COM）

第3章 市場力学、規制、および動向分析

• 市場力学
  • 促進要因
  • 抑制要因
  • 市場機会
• 影響分析
• 再発性多形性膠芽腫治療薬の技術的進歩
• 主な発展
• 買収、コラボレーション、パートナーシップ
• 疫学
• 償還分析
• パイプライン分析
• 価格分析
• 治療アルゴリズム

第4章 世界の再発性多形性膠芽腫治療薬市場：COVID-19の影響

• COVID前の状況
• COVID後の需要
• 再発性多形性膠芽腫治療薬の必要性
• 推奨事項とガイドライン：規制当局別

第5章 世界の再発性多形性膠芽腫治療薬市場：治療法別（2017～2028年（100万米ドル））

• イントロダクション
• 経口薬
• 放射線増感剤
• ニトロソウレア薬
• 化学療法

第6章 世界の再発性多形性膠芽腫治療薬市場：タイプ別（2017～2028年（100万米ドル））

• イントロダクション
• グレードIIまたはグレードIII
• グレードIV
• その他

第7章 世界の再発性多形性膠芽腫治療薬市場：地域別（2017～2028年（100万米ドル））

• イントロダクション
• 北米
• 欧州
• アジア太平洋
• ラテンアメリカ
• アフリカ
• 中東

第8章 競合情勢

• 企業プロファイル
  • GlaxoSmithKline, Plc.
  • Astrazeneca
  • F. Hoffman-La Roche, Ltd.
  • Pfizer, Inc.
  • Merck & Co., Inc.
  • Vascular Biogeneics
  • AngioChem, Inc.
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Boston Biomedical, Inc.
  • Cantex Pharmaceuticals, Inc.
  • Celldex Therapeutics, Inc.
  • Cavion LLC
  • Coherus BioSciences, Inc.
  • Eisai
  • Eli Lilly and Company
  • Cortice Biosciences, Inc.
  • EnGeneIC Ltd.
  • GenSpera, Inc.
  • ERC Belgium SA
  • Genzyme Corporation
  • ImmunoCellular Therapeutics, Ltd.
  • GW Pharmaceuticals Plc.

第9章 セクション

Glioblastoma multiforme or GBM is an aggressive and the most common form of brain cancer that involves glial cells. Gliomas are rapidly developing tumors that develop from the star-shaped glial cells present in the spinal cord or brain. Recurrent glioblastoma multiforme is a possibility of reoccurrence of GBM after tumor surgery. This is because it is difficult to wholly remove the tumor during surgery and there is always a possibility that after a period of remission, cancer might recur. The symptoms of GBM include constant headaches, seizures, vomiting, difficulty in speaking, and double or blurred vision.

Market Dynamics

The rising incidence of brain cancers is expected to drive the recurrent glioblastoma multiforme treatment market growth over the forecast period. Although, researchers believe that egentic mutations may cause this disease, symptoms include seizures, change in mood, loss of appetite, double or blurred vision, change in ability to think and difficulty in speech. According to the statistics provided by the World Health Organization (WHO), each year, around 5 million people are diagnosed with epilepsy across the globe.

Moreover, tuberous sclerosis, neurofibromatosis, von-hippel-lindau disease, turcot syndrome, and Li-fraumeni syndrome are some of the genetic disorders related to the increasing prevalence of gliomas, which is expected to fuel the market growth during the forecast period.

Furthermore, key players in the market are increasingly investing in research & development to develop, create, and commercialize novel drugs, which is expected to create lucrative growth opportunities for the global recurrent glioblastoma multiforme treatment market in the near future. However, lack of effective therapies and the inability of drugs to effectively prevent tumor reoccurrence are predicted to restrict the market growth over the forecast period.

Key features of the study:

• This report provides in-depth analysis of the global recurrent glioblastoma multiforme treatment market, market size (US$ Mn), and compound annual growth rate (CAGR (%)) for the forecast period (2022-2028), considering 2021 as the base year
• It elucidates potential revenue opportunity across different segments and explains an attractive investment proposition matrix for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by leading players
• It profiles key players in the global recurrent glioblastoma multiforme treatment market based on the following parameters - company overview, financial performance, product portfolio, geographical presence, key developments, and strategies
• Key players covered as a part of this study include GlaxoSmithKline plc., AstraZeneca, F. Hoffman-La Roche, Ltd., Pfizer, Inc., Merck & Co., Inc., Vascular Biogeneics, AngioChem, Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Boston Biomedical, Inc., Cantex Pharmaceuticals, Inc., Celldex Therapeutics, Inc., Cavion LLC, Coherus BioSciences, Inc., Eisai, Eli Lilly and Company, Cortice Biosciences, Inc., EnGeneIC Ltd., GenSpera, Inc., ERC Belgium SA, Genzyme Corporation, ImmunoCellular Therapeutics, Ltd., and GW Pharmaceuticals Plc.
• Insights from this report would allow marketers and management authorities of companies to make an informed decision with respect to future product launches, governmental initiatives, technological up-gradation, market expansion, and marketing tactics
• The global recurrent glioblastoma multiforme treatment market report caters to various stakeholders in this industry, including investors, product manufacturers, distributors, and suppliers for recurrent glioblastoma multiforme treatment market, research and consulting firms, new entrants, and financial analysts.

Detailed Segmentation:

• Global Recurrent Glioblastoma Multiforme Treatment Market, By Treatment:
  • Oral Medications
  • Radiosensitizers
  • Nitrosoureas Drugs
  • Chemotherapy
• Global Recurrent Glioblastoma Multiforme Treatment Market, By Type:
  • Grade II or Grade III
  • Grade IV
  • Others
• Global Recurrent Glioblastoma Multiforme Treatment Market, By Region:
  • North America
    • By Country:
  • U.S.
  • Canada
    • By Treatment:
  • Oral Medications
  • Radiosensitizers
  • Nitrosoureas Drugs
  • Chemotherapy
    • By Type:
  • Grade II or Grade III
  • Grade IV
  • Others
  • Europe
    • By Country:
  • U.K.
  • Germany
  • Italy
  • Spain
  • France
  • Russia
  • Rest of Europe
    • By Treatment:
  • Oral Medications
  • Radiosensitizers
  • Nitrosoureas Drugs
  • Chemotherapy
    • By Type:
  • Grade II or Grade III
  • Grade IV
  • Others
  • Asia Pacific
    • By Country:
  • Australia
  • India
  • China
  • Japan
  • ASEAN
  • South Korea
  • Rest of Asia Pacific
    • By Treatment:
  • Oral Medications
  • Radiosensitizers
  • Nitrosoureas Drugs
  • Chemotherapy
    • By Type:
  • Grade II or Grade III
  • Grade IV
  • Others
  • Latin America
    • By Country:
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
    • By Treatment:
  • Oral Medications
  • Radiosensitizers
  • Nitrosoureas Drugs
  • Chemotherapy
    • By Type:
  • Grade II or Grade III
  • Grade IV
  • Others
  • Middle East
    • By Country:
  • GCC
  • Israel
  • Rest of Middle East
    • By Treatment:
  • Oral Medications
  • Radiosensitizers
  • Nitrosoureas Drugs
  • Chemotherapy
    • By Type:
  • Grade II or Grade III
  • Grade IV
  • Others
  • Africa
    • By Region:
  • North Africa
  • Central Africa
  • South Africa
    • By Treatment:
  • Oral Medications
  • Radiosensitizers
  • Nitrosoureas Drugs
  • Chemotherapy
    • By Type:
  • Grade II or Grade III
  • Grade IV
  • Others
• Company Profiles
  • GlaxoSmithKline, Plc.
    • Company Overview
    • Treatment Portfolio
    • Financial Performance
    • Recent Highlights
    • Strategies
  • Astrazeneca
  • F. Hoffman-La Roche, Ltd.
  • Pfizer, Inc.
  • Merck & Co., Inc.
  • Vascular Biogeneics
  • AngioChem, Inc.
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Boston Biomedical, Inc.
  • Cantex Pharmaceuticals, Inc.
  • Celldex Therapeutics, Inc.
  • Cavion LLC
  • Coherus BioSciences, Inc.
  • Eisai
  • Eli Lilly and Company
  • Cortice Biosciences, Inc.
  • EnGeneIC Ltd.
  • GenSpera, Inc.
  • ERC Belgium SA
  • Genzyme Corporation
  • ImmunoCellular Therapeutics, Ltd.
  • GW Pharmaceuticals Plc.

"*" marked represents similar segmentation in other categories in the respective section

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Overview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snippet, By Treatment
  • Market Snippet, By Type
  • Market Snippet, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Impact Analysis
• Technological Advancements in Recurrent Glioblastoma Multiforme Treatment
• Key Developments
• Acquisition, Collaborations & Partnerships
• Epidemiology
• Reimbursement Analysis
• Pipeline Analysis
• Pricing Analysis
• Treatment Algorithm

4. Global Recurrent Glioblastoma Multiforme Treatment Market, Impact of Coronavirus (Covid-19) Pandemic

• Pre-COVID Situation
• Post-COVID Demand
• Need for Recurrent Glioblastoma Multiforme Treatment
• Recommendations and Guidelines by Regulatory Bodies

5. Global Recurrent Glioblastoma Multiforme Treatment Market, By Treatment, 2017 - 2028, (US$ Million)

• Introduction
  • Market Share Analysis, 2022 and 2028 (%)
  • Y-o-Y Growth Analysis, 2017 - 2028
  • Segment Trends
• Oral Medications
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
• Radiosensitizers
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
• Nitrosoureas Drugs
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
• Chemotherapy
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

6. Global Recurrent Glioblastoma Multiforme Treatment Market, By Type, 2017 - 2028, (US$ Million)

• Introduction
  • Market Share Analysis, 2022 and 2028 (%)
  • Y-o-Y Growth Analysis, 2017 - 2028
  • Segment Trends
• Grade II or Grade III
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
• Grade IV
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)
• Others
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2017 - 2028, (US$ Million)

7. Global Recurrent Glioblastoma Multiforme Treatment Market, By Region, 2017 - 2028, (US$ Million)

• Introduction
  • Market Share Analysis, By Region, 2022 and 2028 (%)
  • Y-o-Y Growth Analysis, By Region, 2017 - 2028
  • Regional Trends
• North America
  • Market Size and Forecast, By Treatment, 2017 - 2028, (US$ Million)
  • Market Size and Forecast, By Type, 2017 - 2028, (US$ Million)
  • Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
  • U.S.
  • Canada
• Europe
  • Market Size and Forecast, By Treatment, 2017 - 2028, (US$ Million)
  • Market Size and Forecast, By Type, 2017 - 2028, (US$ Million)
  • Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • Market Size and Forecast, By Treatment, 2017 - 2028, (US$ Million)
  • Market Size and Forecast, By Type, 2017 - 2028, (US$ Million)
  • Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
  • China
  • Japan
  • India
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Latin America
  • Market Size and Forecast, By Treatment, 2017 - 2028, (US$ Million)
  • Market Size and Forecast, By Type, 2017 - 2028, (US$ Million)
  • Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
• Africa
  • Market Size and Forecast, By Treatment, 2017 - 2028, (US$ Million)
  • Market Size and Forecast, By Type, 2017 - 2028, (US$ Million)
  • Market Size and Forecast, By Country/Region, 2017 - 2028, (US$ Million)
  • North Africa
  • Central Africa
  • South Africa
• Middle East
  • Market Size and Forecast, By Treatment, 2017 - 2028, (US$ Million)
  • Market Size and Forecast, By Type, 2017 - 2028, (US$ Million)
  • Market Size and Forecast, By Country, 2017 - 2028, (US$ Million)
  • GCC
  • Israel
  • Rest of Middle East

8. Competitive Landscape

• Company Profiles
  • GlaxoSmithKline, Plc.
  • Company Overview
  • Treatment Portfolio
  • Financial Performance
  • Recent Highlights
  • Strategies
  • Astrazeneca
  • Company Overview
  • Treatment Portfolio
  • Financial Performance
  • Recent Highlights
  • Strategies
  • F. Hoffman-La Roche, Ltd.
  • Company Overview
  • Treatment Portfolio
  • Financial Performance
  • Recent Highlights
  • Strategies
  • Pfizer, Inc.
  • Company Overview
  • Treatment Portfolio
  • Financial Performance
  • Recent Highlights
  • Strategies
  • Merck & Co., Inc.
  • Company Overview
  • Treatment Portfolio
  • Financial Performance
  • Recent Highlights
  • Strategies
  • Vascular Biogeneics
  • Company Overview
  • Treatment Portfolio
  • Financial Performance
  • Recent Highlights
  • Strategies
  • AngioChem, Inc.
  • Company Overview
  • Treatment Portfolio
  • Financial Performance
  • Recent Highlights
  • Strategies
  • Boehringer Ingelheim GmbH
  • Company Overview
  • Treatment Portfolio
  • Financial Performance
  • Recent Highlights
  • Strategies
  • Bristol-Myers Squibb Company
  • Company Overview
  • Treatment Portfolio
  • Financial Performance
  • Recent Highlights
  • Strategies
  • Boston Biomedical, Inc.
  • Company Overview
  • Treatment Portfolio
  • Financial Performance
  • Recent Highlights
  • Strategies
  • Cantex Pharmaceuticals, Inc.
  • Company Overview
  • Treatment Portfolio
  • Financial Performance
  • Recent Highlights
  • Strategies
  • Celldex Therapeutics, Inc.
  • Company Overview
  • Treatment Portfolio
  • Financial Performance
  • Recent Highlights
  • Strategies
  • Cavion LLC
  • Company Overview
  • Treatment Portfolio
  • Financial Performance
  • Recent Highlights
  • Strategies
  • Coherus BioSciences, Inc.
  • Company Overview
  • Treatment Portfolio
  • Financial Performance
  • Recent Highlights
  • Strategies
  • Eisai
  • Company Overview
  • Treatment Portfolio
  • Financial Performance
  • Recent Highlights
  • Strategies
  • Eli Lilly and Company
  • Company Overview
  • Treatment Portfolio
  • Financial Performance
  • Recent Highlights
  • Strategies
  • Cortice Biosciences, Inc.
  • Company Overview
  • Treatment Portfolio
  • Financial Performance
  • Recent Highlights
  • Strategies
  • EnGeneIC Ltd.
  • Company Overview
  • Treatment Portfolio
  • Financial Performance
  • Recent Highlights
  • Strategies
  • GenSpera, Inc.
  • Company Overview
  • Treatment Portfolio
  • Financial Performance
  • Recent Highlights
  • Strategies
  • ERC Belgium SA
  • Company Overview
  • Treatment Portfolio
  • Financial Performance
  • Recent Highlights
  • Strategies
  • Genzyme Corporation
  • Company Overview
  • Treatment Portfolio
  • Financial Performance
  • Recent Highlights
  • Strategies
  • ImmunoCellular Therapeutics, Ltd.
  • Company Overview
  • Treatment Portfolio
  • Financial Performance
  • Recent Highlights
  • Strategies
  • GW Pharmaceuticals Plc.
  • Company Overview
  • Treatment Portfolio
  • Financial Performance
  • Recent Highlights
  • Strategies

9. Section

• References
• Research Methodology
• About us and Sales Contact